Crossref
FDA approves another OTC naloxone nasal spray
Alcoholism & Drug Abuse Weekly · 29.06.2026 · 38 (26) · 8-8
DOI: 10.1002/adaw.34967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alcoholism & Drug Abuse Weekly, online erschienen am 02.07.2026. Verfasst von Alison Knopf.
Abstract (Originalsprache)
The U.S. Food and Drug Administration (FDA) on June 16 approved another over‐the‐counter (OTC) intranasal naloxone product, Rextovy, a 4‐milligram naloxone hydrochloride nasal spray for the treatment of opioid overdose.
Zitieren
APA
Knopf, A. (2026). FDA approves another OTC naloxone nasal spray. Alcoholism & Drug Abuse Weekly, 38(26), 8-8. https://doi.org/10.1002/adaw.34967
Vancouver
Knopf A. FDA approves another OTC naloxone nasal spray. Alcoholism & Drug Abuse Weekly. 2026;38(26):8-8. doi:10.1002/adaw.34967
BibTeX
@article{Knopf2026,
author = {Knopf, Alison},
title = {FDA approves another OTC naloxone nasal spray},
journal = {Alcoholism & Drug Abuse Weekly},
year = {2026},
volume = {38},
number = {26},
pages = {8--8},
doi = {10.1002/adaw.34967}
}
EUVIMED